Insight Molecular Diagnostics (IMDX) Return on Sales (2020 - 2025)
Insight Molecular Diagnostics' Return on Sales history spans 6 years, with the latest figure at 42.49% for Q3 2025.
- For Q3 2025, Return on Sales rose 7503.0% year-over-year to 42.49%; the TTM value through Sep 2025 reached 13.93%, up 2454.0%, while the annual FY2024 figure was 32.45%, 3050.0% down from the prior year.
- Return on Sales for Q3 2025 was 42.49% at Insight Molecular Diagnostics, down from 19.0% in the prior quarter.
- Across five years, Return on Sales topped out at 97.78% in Q3 2023 and bottomed at 117.52% in Q3 2024.
- The 5-year median for Return on Sales is 9.85% (2023), against an average of 14.43%.
- The largest annual shift saw Return on Sales soared 61664bps in 2021 before it crashed -21531bps in 2024.
- A 5-year view of Return on Sales shows it stood at 18.4% in 2021, then rose by 15bps to 21.18% in 2022, then plummeted by -109bps to 1.95% in 2023, then crashed by -1062bps to 22.63% in 2024, then plummeted by -88bps to 42.49% in 2025.
- Per Business Quant, the three most recent readings for IMDX's Return on Sales are 42.49% (Q3 2025), 19.0% (Q2 2025), and 3.18% (Q1 2025).